Nurtec ODT Now Approved to Help Prevent Episodic Migraine, Too

Nurtec ODT (rimegepant) was first approved in February 2020 by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults. Now, the FDA has given the green light to Nurtec ODT to help prevent episodic migraines, too — making it the first migraine medication approved for both acute and preventive treatment.